BRPI0508607A - conjugados de amido de hidroxialquila e uma proteìna, preparados pela aminação redutiva - Google Patents

conjugados de amido de hidroxialquila e uma proteìna, preparados pela aminação redutiva

Info

Publication number
BRPI0508607A
BRPI0508607A BRPI0508607-8A BRPI0508607A BRPI0508607A BR PI0508607 A BRPI0508607 A BR PI0508607A BR PI0508607 A BRPI0508607 A BR PI0508607A BR PI0508607 A BRPI0508607 A BR PI0508607A
Authority
BR
Brazil
Prior art keywords
conjugates
hydroxyalkyl starch
protein
starch
hydroxyalkyl
Prior art date
Application number
BRPI0508607-8A
Other languages
English (en)
Inventor
Norbert Zander
Wolfram Eichner
Harald Conradt
Frank Hacket
Klaus Langer
Michele Orlando
Ronald Frank
Original Assignee
Fresenius Kabi De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi De Gmbh filed Critical Fresenius Kabi De Gmbh
Publication of BRPI0508607A publication Critical patent/BRPI0508607A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C08B31/006—Crosslinking of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C08B31/185—Derivatives of oxidised starch, e.g. crosslinked oxidised starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)

Abstract

CONJUGADOS DE AMIDO DE HIDROXIALQUILA E UMA PROTEìNA, PREPARADOS PELA ANIMAçãO REDUTIVA. A presente invenção refere-se aos conjugados de amido de hidroxialquila, preferivelmente amido de hidroxietila, e uma proteína, em que estes conjugados são formados por uma reação de animação reductiva entre pelo menos um grupo de aldeído ou grupo ceto ou grupo hemiacetal do amido de hidroxialquila ou de um derivado do amido de hidroxialquila, e pelo menos um grupo de amino da proteína, de modo que o amido de hidroxialquila ou o seu derivado é covalentemente ligado à proteína através de uma ligação de azometina ou uma ligação de amino. A presente invenção também se refere ao método de produção destes conjugados e usos específicos dos conjugados.
BRPI0508607-8A 2004-03-11 2005-03-11 conjugados de amido de hidroxialquila e uma proteìna, preparados pela aminação redutiva BRPI0508607A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55221704P 2004-03-11 2004-03-11
EP04005855 2004-03-11
PCT/EP2005/002653 WO2005092928A1 (en) 2004-03-11 2005-03-11 Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination

Publications (1)

Publication Number Publication Date
BRPI0508607A true BRPI0508607A (pt) 2007-07-31

Family

ID=34924481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508607-8A BRPI0508607A (pt) 2004-03-11 2005-03-11 conjugados de amido de hidroxialquila e uma proteìna, preparados pela aminação redutiva

Country Status (17)

Country Link
US (1) US8287850B2 (pt)
EP (2) EP1725589A1 (pt)
JP (1) JP5191729B2 (pt)
KR (1) KR101186821B1 (pt)
CN (2) CN1946742A (pt)
AR (1) AR048035A1 (pt)
AU (1) AU2005225513B2 (pt)
BR (1) BRPI0508607A (pt)
CA (1) CA2558738C (pt)
DE (1) DE202005021885U1 (pt)
EA (1) EA010501B1 (pt)
IL (1) IL177730A (pt)
NO (1) NO20064631L (pt)
SG (1) SG151261A1 (pt)
TW (1) TWI417303B (pt)
WO (1) WO2005092928A1 (pt)
ZA (1) ZA200607251B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2004024761A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
BRPI0413450A (pt) * 2003-08-08 2006-10-17 Fresenius Kabi De Gmbh conjugados de hidroxialquil amido e g-csf
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1732609B1 (en) * 2004-03-11 2012-07-11 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
EP2043693B1 (en) * 2006-07-25 2016-04-27 Lipoxen Technologies Limited N-terminal derivatisation of insulin with polysialic acid
EP2197919B1 (en) 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
NZ598193A (en) * 2007-12-27 2012-12-21 Baxter Int Chemically Modified Factor IX
AU2009242038B2 (en) 2008-05-02 2013-05-30 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
MX2010012044A (es) * 2008-05-06 2011-05-19 Octapharma Ag Complejo que comprende proteinas de union a heparina y conjugados de heparina-almidon de hidroxialquilo.
GB0811743D0 (en) 2008-06-26 2008-07-30 Hemosol Biopharma Inc Composition
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP2383035A4 (en) 2008-12-03 2017-11-22 Kaneka Corporation Formyl group-containing porous support, adsorbent using same, method for producing same, and method for producing the adsorbent
BRPI1009889A2 (pt) * 2009-03-20 2016-03-15 Fpinnovations material celulósico, lignocelulósico ou de celulose modificado, processo para produzir um material celulósico, lignocelulósico ou de celulose modificado, e, papel
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
CN102666578A (zh) 2009-12-21 2012-09-12 Ambrx公司 经过修饰的猪促生长素多肽和其用途
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
CA3078259A1 (en) * 2010-04-20 2011-10-27 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP2741780A1 (en) 2011-08-10 2014-06-18 Ludwig-Maximilians-Universität München Method for the controlled intracellular delivery of nucleic acids
CN103917245B (zh) * 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
WO2013089182A1 (ja) * 2011-12-14 2013-06-20 国立大学法人筑波大学 新規分岐ポリエチレングリコール及びその用途
WO2013113503A1 (en) 2012-01-31 2013-08-08 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and an oligonucleotide
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
CN105008548B (zh) 2012-12-27 2020-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
MX2017004488A (es) 2014-10-23 2017-07-17 Ngm Biopharmaceuticals Inc Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
MY190974A (en) 2015-05-20 2022-05-25 Massachusetts Gen Hospital Shared neoantigens
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3302528A1 (en) 2015-05-29 2018-04-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
CA3039897C (en) * 2016-10-11 2023-04-18 Arkema Inc. Hollow polymer particles for thermal insulation
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
EA202090090A1 (ru) 2017-07-11 2020-06-09 Синторкс, Инк. Включение неприродных нуклеотидов и способы с ними
TW202248207A (zh) 2017-08-03 2022-12-16 美商欣爍克斯公司 用於增生及感染性疾病治療之細胞激素結合物
JP2021501221A (ja) 2017-11-10 2021-01-14 アーモ・バイオサイエンシーズ・インコーポレイテッドＡｒｍｏ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 免疫チェックポイント経路阻害剤と併用したインターロイキン−１０の組成物および使用方法
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CN108837299B (zh) * 2018-07-18 2020-08-07 武汉大学 一种智能调节血糖的微针贴片及其制备方法
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
BR112021012278A2 (pt) 2018-12-21 2021-12-14 Biontech Us Inc Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
AU2020218203A1 (en) 2019-02-06 2021-08-26 Synthorx, Inc. IL-2 conjugates and methods of use thereof
CA3141084A1 (en) 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
WO2022132596A2 (en) 2020-12-14 2022-06-23 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
CN115477442B (zh) * 2022-08-16 2023-09-26 杭州鲲宸环境科技有限公司 一种航材园废水处理方法
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3191291A (en) * 1959-01-21 1965-06-29 Continental Can Co Art of producing very thin steel and like sheets in wide strips
CH397115A (de) 1960-10-04 1965-08-15 Hoechst Ag Verfahren zur Herstellung wasserunlöslicher Farbstoffe
GB1385403A (en) 1971-07-14 1975-02-26 Unilever Ltd Process for preparing oxidised carbohydrates
GB1419080A (en) 1972-12-29 1975-12-24 Cheminova As Chemical compounds having juvenile hormone activity
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4125492A (en) 1974-05-31 1978-11-14 Pedro Cuatrecasas Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
FR2309082A1 (fr) 1975-04-24 1976-11-19 Serras Paulet Edouard Dispositif a bouton poussoir de commande de commutation d'un circuit electronique ou electrique
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
FR2378094A2 (fr) 1977-01-24 1978-08-18 Inst Nat Sante Rech Med Nouveaux reactifs biologiques constitues par des supports solides sur lesquels sont couples des composes organiques comportant un residu glucidique
SE420847B (sv) * 1978-11-14 1981-11-02 Svenska Rayon Ab Forfarande for framstellning av krusiga modalfibrer
EP0019403B1 (en) 1979-05-10 1985-07-31 American Hospital Supply Corporation Hydroxyalkyl-starch drug carrier
DE3029307A1 (de) * 1980-08-01 1982-03-04 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Haemoglobin enthaltendes blutersatzmittel
US4454161A (en) * 1981-02-07 1984-06-12 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for the production of branching enzyme, and a method for improving the qualities of food products therewith
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4965825A (en) * 1981-11-03 1990-10-23 The Personalized Mass Media Corporation Signal processing apparatus and methods
US5508815A (en) * 1981-12-14 1996-04-16 Smart Vcr Limited Partnership Schedule display system for video recorder programming
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
DK171029B1 (da) 1983-10-11 1996-04-22 Fidia Spa Hyaluronsyrefraktion, fremgangsmåde til fremstilling deraf samt ophthalmiske præparater indeholdende hyaluronsyrefraktion
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
DE3501616A1 (de) 1985-01-17 1986-07-17 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von hydroxylamin-derivaten
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4863964A (en) 1985-07-02 1989-09-05 Biomedical Frontiers, Inc. Method for the stabilization of deferoxamine to chelate free ions in physiological fluid
US5217998A (en) * 1985-07-02 1993-06-08 Biomedical Frontiers, Inc. Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
US5362853A (en) 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP2594123B2 (ja) * 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0307827A3 (en) 1987-09-15 1989-12-27 Kuraray Co., Ltd. Novel macromolecular complexes, process for producing same and medicinal use of such complexes
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DK110188D0 (da) 1988-03-02 1988-03-02 Claus Selch Larsen High molecular weight prodrug derivatives of antiinflammatory drugs
FR2630329B1 (fr) 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
IT1219942B (it) 1988-05-13 1990-05-24 Fidia Farmaceutici Esteri polisaccaridici
US4900780A (en) * 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
DE3836600A1 (de) 1988-10-27 1990-05-03 Wolff Walsrode Ag Kohlensaeureester von polysacchariden und verfahren zu ihrer herstellung
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US6261800B1 (en) * 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
DE19975071I2 (de) * 1989-06-16 2000-02-03 Fresenius Ag Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
JP2896580B2 (ja) 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
JP2838800B2 (ja) 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
JP2909239B2 (ja) * 1991-03-27 1999-06-23 株式会社東芝 高能率符号化記録再生装置
DK130991D0 (da) * 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
DE4130807A1 (de) * 1991-09-17 1993-03-18 Wolff Walsrode Ag Verfahren zur herstellung von polysaccharidcarbonaten
JP3428033B2 (ja) * 1992-02-19 2003-07-22 株式会社日立製作所 ディジタルｖｔｒ
DE69325415T2 (de) * 1992-05-18 1999-11-25 Canon K.K., Tokio/Tokyo Datenverarbeitungsvorrichtung
US6172208B1 (en) 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
FI935485A (fi) 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
US5659350A (en) * 1992-12-09 1997-08-19 Discovery Communications, Inc. Operations center for a television program packaging and delivery system
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
CA2110543A1 (en) 1992-12-09 1994-06-10 David E. Wright Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
ATE352170T1 (de) * 1992-12-09 2007-02-15 Sedna Patent Services Llc Menugesteuertes fernsehprogrammzugangssystem und verfahren
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5805762A (en) * 1993-01-13 1998-09-08 Hitachi America, Ltd. Video recording device compatible transmitter
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JP2594241B2 (ja) 1993-03-16 1997-03-26 ヘモソール インコーポレイテッド 酸化開環サッカライドによるヘモグロビンの選択的架橋
US5543927A (en) * 1993-04-29 1996-08-06 Sony Corporation Variable speed playback of digital video stored in a non-tape media
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6275268B1 (en) * 1993-09-09 2001-08-14 United Video Properties, Inc. Electronic television program guide with remote product ordering
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
JPH07188291A (ja) 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
US5606359A (en) * 1994-06-30 1997-02-25 Hewlett-Packard Company Video on demand system with multiple data sources configured to provide vcr-like services
EP0727125B1 (en) * 1994-08-09 2002-01-02 Koninklijke Philips Electronics N.V. Apparatus for recording and/or reproducing video signals and audio signals in/from inclined tracks on a magnetic tape, and magnetic tape for such apparatus
US5625406A (en) * 1994-12-21 1997-04-29 Thomson Consumer Electronics, Inc. Unified program guide interface
KR0150702B1 (ko) * 1995-01-25 1998-10-15 구자홍 브이오디 시스템의 고속 정/역 주행 제어 방법
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5748254A (en) * 1995-07-24 1998-05-05 Coach Master International Corporation Systems with a remote control in which information can be retrieved from an encoded, laser readable disc
WO1997021452A2 (en) 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
US5723589A (en) * 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
KR100205549B1 (ko) * 1996-05-06 1999-07-01 윤종용 브이.오.디. 용 셋탑보드 및 셋탑보드가 장착된 컴퓨터 시스템
US5696152A (en) 1996-05-07 1997-12-09 Wisconsin Alumni Research Foundation Taxol composition for use as organ preservation and cardioplegic agents
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6065050A (en) * 1996-06-05 2000-05-16 Sun Microsystems, Inc. System and method for indexing between trick play and normal play video streams in a video delivery system
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5851984A (en) 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR100204575B1 (ko) * 1996-10-17 1999-06-15 정선종 위성 제어 센터에서 원격 측정 데이타의 압축저장 및 검색 방법
US6177931B1 (en) * 1996-12-19 2001-01-23 Index Systems, Inc. Systems and methods for displaying and recording control interface with television programs, video, advertising information and program scheduling information
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
CA2299271C (en) * 1997-08-07 2009-02-03 University Of Utah Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof
US6378130B1 (en) * 1997-10-20 2002-04-23 Time Warner Entertainment Company Media server interconnect architecture
US6875594B2 (en) * 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6172712B1 (en) * 1997-12-31 2001-01-09 Intermec Ip Corp. Television with hard disk drive
US6938268B1 (en) * 1998-01-08 2005-08-30 Winston W. Hodge Video stream sharing
DE19808079A1 (de) 1998-02-20 1999-08-26 Schering Ag Hydroxyethylstärke-Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US6596135B1 (en) * 1998-03-05 2003-07-22 Asahi Glass Company, Limited Sputtering target, transparent conductive film, and method for producing the same
JP4014281B2 (ja) * 1998-03-19 2007-11-28 富士通株式会社 Ｃａｔｖにおける番組予約方式
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6510554B1 (en) * 1998-04-27 2003-01-21 Diva Systems Corporation Method for generating information sub-streams for FF/REW applications
JPH11339374A (ja) * 1998-05-26 1999-12-10 Yamaha Corp ディジタル記録装置
US6233389B1 (en) * 1998-07-30 2001-05-15 Tivo, Inc. Multimedia time warping system
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
US6389218B2 (en) * 1998-11-30 2002-05-14 Diva Systems Corporation Method and apparatus for simultaneously producing compressed play and trick play bitstreams from a video frame sequence
EP1035137A1 (en) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US20020065410A1 (en) * 1999-12-02 2002-05-30 Antrim Richard L. Branched starches and branched starch hydrolyzates
US6549718B1 (en) * 1999-12-22 2003-04-15 Spotware Technologies, Inc. Systems, methods, and software for using markers on channel signals to control electronic program guides and recording devices
US6351596B1 (en) * 2000-01-07 2002-02-26 Time Warner Entertainment Co, Lp Content control of broadcast programs
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2001294601A (ja) 2000-04-11 2001-10-23 Akita Prefecture 高度分岐澱粉と該高度分岐澱粉の製造方法
JP2002003398A (ja) 2000-04-17 2002-01-09 Ltt Institute Co Ltd 徐放製剤、その製造法及びワクチン
US6442328B1 (en) * 2000-05-31 2002-08-27 Keen Personal Media, Inc. Digital video recorder connectable to an auxiliary interface of a set-top box that provides video data stream to a display device based on selection between recorded video signal received from the dig
US6853728B1 (en) * 2000-07-21 2005-02-08 The Directv Group, Inc. Video on demand pay per view services with unmodified conditional access functionality
US6417347B1 (en) * 2000-08-24 2002-07-09 Scimed Life Systems, Inc. High yield S-nitrosylation process
DE10041541A1 (de) 2000-08-24 2002-03-14 Michael Duchene Rekombinante Allergene aus der Motte Plodia interpunctella
EP1315513B1 (en) 2000-09-08 2011-03-09 Amylin Pharmaceuticals, Inc. "pseudo"-native chemical ligation
GB0022370D0 (en) * 2000-09-13 2000-10-25 Pace Micro Tech Plc Improvements to televisionn system
KR20120032046A (ko) * 2000-10-11 2012-04-04 유나이티드 비디오 프로퍼티즈, 인크. 매체 콘텐츠 배달 시스템 및 방법
US20020056970A1 (en) * 2000-11-13 2002-05-16 Groth Michael C. Variably adjustable wheelchair apparatus
US7530086B2 (en) * 2000-12-12 2009-05-05 Hewlett-Packard Development Company, L.P. Media program timing and identity delivery method and system
DE10105921A1 (de) 2001-02-09 2002-08-14 Braun Melsungen Ag An Kolloide gebundene Arzneiwirkstoffe
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10126158A1 (de) 2001-05-30 2002-12-12 Novira Chem Gmbh Eine Methode zur Synthese von Gemischen einfach aktivierter und nicht aktivierter Polyoxyalkylene zur Modifizierung von Proteinen
DE10129369C1 (de) 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
DE10135694A1 (de) 2001-07-21 2003-02-06 Supramol Parenteral Colloids Amphiphile Stärke-und Hydroxyethylstärke-Konjugate
US20030093800A1 (en) * 2001-09-12 2003-05-15 Jason Demas Command packets for personal video recorder
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
DE50214456D1 (de) 2001-10-26 2010-07-08 Noxxon Pharma Ag Modifizierte l-nukleinsäure
US6375846B1 (en) * 2001-11-01 2002-04-23 Harry Wellington Jarrett Cyanogen bromide-activation of hydroxyls on silica for high pressure affinity chromatography
DE10155098A1 (de) 2001-11-09 2003-05-22 Supramol Parenteral Colloids Mittel zur Prävention von mykotischen Kontaminationen bei der Zell- und Gewebekultur bakteriellen, pflanzlichen, animalischen und humanen Ursprungs, bestehend aus Polyen-Makrolid-Konjugaten mit Polysacchariden
JP2003179836A (ja) * 2001-12-07 2003-06-27 Sony Corp サーバ装置、端末装置、番組記録制御システム及び番組記録制御方法
US6916962B2 (en) * 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DE10207072A1 (de) 2002-02-20 2003-08-28 Supramol Parenteral Colloids Stärkederivate, ihre Konjugate und Verfahren zur Herstellung derselben
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
ATE368066T1 (de) 2002-03-13 2007-08-15 Beijing Jiankai Technology Co Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
DE10217994A1 (de) 2002-04-23 2003-11-06 Supramol Parenteral Colloids Konjugate von hyperverzweigten Polysacchariden
US8443383B2 (en) * 2002-05-03 2013-05-14 Time Warner Cable Enterprises Llc Use of messages in program signal streams by set-top terminals
US7614066B2 (en) * 2002-05-03 2009-11-03 Time Warner Interactive Video Group Inc. Use of multiple embedded messages in program signal streams
US8312504B2 (en) * 2002-05-03 2012-11-13 Time Warner Cable LLC Program storage, retrieval and management based on segmentation messages
AU2003249692B2 (en) * 2002-06-03 2008-07-31 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20040101546A1 (en) 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
ES2897470T3 (es) * 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
EP1591467A1 (en) 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
ES2214166T1 (es) 2002-09-11 2004-09-16 Fresenius Kabi Deutschland Gmbh Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
WO2004024761A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1549350B1 (en) * 2002-10-08 2008-09-24 Fresenius Kabi Deutschland GmbH Pharmaceutically active oligosaccharide conjugates
DE10254745A1 (de) 2002-11-23 2004-06-03 Supramol Parenteral Colloids Gmbh Imidazolide von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
DE10256558A1 (de) 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
KR101154343B1 (ko) 2003-08-08 2012-07-05 프레제니우스 카비 도이치란트 게엠베하 히드록시알킬 스타치 및 ｇ-ｃｓｆ의 컨쥬게이트
BRPI0413450A (pt) 2003-08-08 2006-10-17 Fresenius Kabi De Gmbh conjugados de hidroxialquil amido e g-csf
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
EP1713508A2 (en) 2004-01-29 2006-10-25 Biosynexus Incorporated Use of amino-oxy functional groups in the preparation of vaccine conjugates
DE102004009783A1 (de) 2004-02-28 2005-09-15 Supramol Parenteral Colloids Gmbh Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
TW200603818A (en) 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
EP1732609B1 (en) 2004-03-11 2012-07-11 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein
WO2005112954A1 (en) 2004-05-14 2005-12-01 William Marsh Rice University Nitric oxide releasing compositions and associated methods
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
WO2007053292A2 (en) 2005-10-31 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
JP2009093397A (ja) * 2007-10-09 2009-04-30 Panasonic Corp タッチパネル及びこれを用いた入力装置
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
MX2011003738A (es) 2008-10-07 2011-09-30 Rexahn Pharmaceuticals Inc Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.

Also Published As

Publication number Publication date
NO20064631L (no) 2006-12-11
ZA200607251B (en) 2009-03-25
TWI417303B (zh) 2013-12-01
EP1725589A1 (en) 2006-11-29
KR101186821B1 (ko) 2012-09-28
CA2558738A1 (en) 2005-10-06
KR20070012400A (ko) 2007-01-25
EA010501B1 (ru) 2008-10-30
EP2336192A1 (en) 2011-06-22
US8287850B2 (en) 2012-10-16
AU2005225513B2 (en) 2012-01-12
EA200601672A1 (ru) 2007-04-27
TW200600519A (en) 2006-01-01
CN101659704A (zh) 2010-03-03
AR048035A1 (es) 2006-03-22
DE202005021885U1 (de) 2011-03-03
IL177730A (en) 2013-11-28
WO2005092928A1 (en) 2005-10-06
AU2005225513A1 (en) 2005-10-06
JP5191729B2 (ja) 2013-05-08
CA2558738C (en) 2013-02-05
IL177730A0 (en) 2006-12-31
CN1946742A (zh) 2007-04-11
JP2007527892A (ja) 2007-10-04
US20070134197A1 (en) 2007-06-14
SG151261A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
BRPI0508607A (pt) conjugados de amido de hidroxialquila e uma proteìna, preparados pela aminação redutiva
BRPI0508628A (pt) conjugados de hidroxialquil amido e uma proteìna
CY1118988T1 (el) Τροποποιημενα σακχαριδια
BRPI0614839A2 (pt) fator vii e fator viia glicopeguilados
WO2008012542A3 (en) Polysaccharide derivatives of erythropoietin
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
BRPI0608076A2 (pt) método de seleção, processo para purificação de oligÈmeros beta-a não difusìveis, anticorpos seletivos contra os ditos oligÈmeros beta-a não difusìveis e um processo para fabricação dos ditos anticorpos
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
BRPI0611872B8 (pt) reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
BRPI0417341A (pt) fator ix glicopeguilado
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
BR0309868A (pt) Conjugados de derivados de caliqueamicina - veìculo
HUP0002189A2 (hu) Eljárás oldalláncukban módosított epotilonok előállítására és az így előállított vegyületek
CY1113346T1 (el) Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου
CY1109084T1 (el) Προϊον ζαχαροπλαστικης με χαμηλα λιπαρα
WO2006072921A3 (en) Sweetener composition of stevia extract and maltol and processes of preparation thereof
BR0208265A (pt) Redução estereosseletiva de acetofenona substituìda
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
GEP20135733B (en) Novel diazeniumdiolate derivatives, their preparation method and pharmaceutical compositions containing them
BRPI0606619A2 (pt) método de análise de oligossacarìdeos, a partir do plasma sangüìneo
BR0316493A (pt) ésteres de ácido aldÈnico, métodos para produzir os mesmos, e métodos para produzir ingredientes ativos farmacêuticos ligados a polissacarìdicos ou derivados polissacarìdeos sobre grupos amino livres
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/18 (2006.01), A61K 38/19 (2006.01), A61K 3